Loss of cBAF Complex Confers Sorafenib Resistance in Liver Cancer
Jacqueline A. Brinkman, Margarita M. Dzama, Max Bucklan, Carl J. Manner, Mallory Sokolowski, Jesse R. Raab
This study identifies the cBAF complex as a driver of sorafenib resistance in liver cancer by disrupting hepatocyte lineage identity and promoting a mesenchymal drug-tolerant state.
bioRxiv · Jun 12, 2026 · PreprintCancer Biology